Cyclosporine A for the treatment of autoimmune disorders in HCV infected patients

Autoimmunity Reviews

Volumn 5, Issue 7, 2006, Pages 493-498

  Galeazzi, Mauro ^a   Bellisai, Francesca ^a   Manganelli, Stefania ^a   Morozzi, Gabriella ^a   Sebastiani, Gian Domenico ^b  

^a UNIVERSITY HOSPITAL OF SIENA   (Italy)

^b UOC di Reumatologia AO San Camillo Forlanini Roma ^*  (Italy)

Author keywords

Anti TNF; Autoimmune disorders; Cyclosporine A; HCV infection; Immunosuppressant

Indexed keywords

ADALIMUMAB; ALPHA INTERFERON; ANTIVIRUS AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; PREDNISONE; RIBAVIRIN; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

AUTOIMMUNE DISEASE; DRUG SAFETY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER TRANSPLANTATION; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS; VIRUS INHIBITION;

AUTOIMMUNE DISEASES; CYCLOSPORINE; HEPATITIS C; HUMANS;

EID: 33747165641     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2006.01.002     Document Type: Review

References (30)

1. Berenguer M., Lopez-Labrador F.X., and Wright T.L. Hepatitis C and liver transplantation. J Hepatol 35 (2001) 666-678
2. Wright T.L., Donegan E., Hsu H.H., Ferrell L., Lake J.R., Kim M., et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 103 (1992) 317-322
3. Chazouilleres O., Kim M., Combs C., Ferrell L., Bacchetti P., Roberts J., et al. Quantitation of hepatitis C virus RNA in liver transplant recipients. Gastroenterology 106 (1994) 994-999
4. Berenguer M., Ferrell L., Watson J., Prieto M., Kim M., Rayon M., et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 32 4 (Apr 2000) 673-684
5. McCaughan G.W. Immunosuppression for HCV following liver transplantation: enough is just enough. Transplantation 78 (2004) 1413-1414
6. 0 monitoring in de novo liver transplantation. Transplantation 77 (2004) 1632-1638
7. Casanovas Taltavull T. Impact of cyclosporine on the development of immunosuppressive therapy in liver transplantation. Transplant Proc 36 (2004) S291-S294
8. Kugelmas M., Osgood M.J., Trotter J.F., Bak T., Wachs M., Forman L., et al. Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection. Liver Transpl 9 (2003) 1159-1165
9. Ghobrial R.M., Farmer D.G., Baquerizo A., Colquhoun S., Rosen H.R., Yersiz H., et al. Orthotopic liver transplantation for hepatitis C: outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center cells. Transplant Proc 37 10 (Dec 2005) 4598-4602
10. Berenguer M., Crippin J., Gish R., Bass N., Bostrom A., Netto G., et al. A model to predict severe HCV-related disease following liver transplantation. Hepatology 38 (2003) 34-41
11. Duvoux C., Mennecier D., and Pageaux G. Immunosuppression with tacrolimus and absence of antihypertensive therapy are associated with fibrosis progression after hepatitis C virus graft reinfection. International society of transplantation congress (2002) abs. 2652
12. Nakamuta M., Kohjima M., Fukushima M., Morizono S., Kotoh K., Kobayashi N., et al. Cyclosporine suppresses cell growth and collagen production in hepatic stellate cells. Transplant Proc 37 10 (Dec 2005) 4598-4602
13. Inoue K., Sekiyama K., Yamada M., Watanabe T., Yasuda H., and Yoshiba M. Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial. J Gastroenterol 38 (2003) 567-572
14. Everson G.T. Impact of immunosuppressive therapy on recurrence of hepatitis C. Liver Transpl 8 (2002) 19-27
15. Lohmann V., Korner F., Koch J., Herian U., Theilmann L., and Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285 5424 (Jul 2 1999) 110-113
16. Watashi K., Hijikata M., Hosaka M., Yamaji M., and Shimotohno K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 38 5 (2003) 1282-1288
17. Sebastiani G.D., Bellisai F., Caudai C., Rottoli P., Valensin P.E., Pippi L., et al. Association of extrahepatic manifestations with HLA class II alleles and with virus genotype in HCV infected patients. J Biol Regul Homeost Agents 19 1-2 (Jan-Jun 2005) 17-22
18. Galeazzi M., Manganelli S., Bellisai F., and Gonnelli L. HCV e malattie autoimmuni. Riv It Biol Med 16 (1996) 91-101
19. Miura H., Itoh Y., Matsumoto Y., Tani M., Tanabe N., Isonokami M., et al. Long-term administration of cyclosporin A to HCV-antibody-positive patients with dermatologic diseases. Int J Dermatol 38 4 (Apr 1999) 310-314
20. Galeazzi M., Bellisai F., Sebastiani G.D., Giannitti C., and Garcia Gonzales E. Utilizzo della ciclosporina in pazienti HCV positivi. Reumatismo 57 4 (2005) 122-124 [numero speciale 3]
21. Donvito A., Bellisai F., Morozzi G., Crisanti A., and Galeazzi M. La ciclosporina A nel trattamento dei disordini autoimmuni in pazienti con infezione cronica da HCV: studio pilota in aperto. Reumatismo 57 4 (2005) 265 [(numero speciale 3) abstract C03]
22. Safety update on TNF-α antagonists: infliximab and etanercept. Food and Drug Administration, Arthritis Drugs Advisory Committee, 17 August 2001. Available at: www.fda/gov/ohrms/dockets/ac/01/transcripts/3779+2_01.pdf [accessed 29 July 2004].
23. Ellerin T., Rubin R.H., and Weinblatt M.E. Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum 48 (2003) 3013-3022
24. Di Bisceglie A.M., and Hoofnagle J.H. Optimal therapy of hepatitis C. Hepatology 36 (2002) S121-S127
25. Lindsay K.L. Introduction to therapy of hepatitis C. Hepatology 36 (2002) S114-S120
26. Calabrese L.H., Zein N., and Vassilopoulos D. Safety of anti-tumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis 63 Suppl 2 (Nov 2004) ii18-ii24
27. Diepolder H.M., Zachoval R., Hoffmann R.M., Wierenga E.A., Santantonio T., Jung M.C., et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 346 (1995) 1006-1007
28. Tsai S.L., Liaw Y.F., Chen M.H., Huang C.Y., and Kuo G.C. Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology 25 (1997) 449-458
29. Zein N.N. A phase II randomised, double blind, placebo controlled study of tumor necrosis factor antagonist (Etanercept, Enbrel) as an adjuvant to interferon and ribavirin in naive patients with chronic hepatitis C [abstract]. Hepatology 36 (2002) 504A
30. Peterson J.R., Hsu F.C., Simkin P.A., and Wener M.H. Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 62 (2003) 1078-1082